EMA begins rolling review of another Covid-19 vaccine

The European Medicines Agency will assess the potential vaccine being developed by Valneva as data trickles in.

Photo: Stephane Mahe/REUTERS / X02520

The European Medicines Agency (EMA) has initiated a rolling review for biotech company Valneva's Covid-19 vaccine candidate, the EMA announces in a news release.

This means that Valneva can submit data in smaller chunks, instead of having to deliver a full data package to the EMA, cutting down on case processing overall.

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs